145 related articles for article (PubMed ID: 20620527)
1. A possible role of hepcidin in the pathogenesis of anemia in heart allograft recipients.
Przybylowski P; Malyszko J; Malyszko JS
Transplant Proc; 2010 Jun; 42(5):1803-7. PubMed ID: 20620527
[TBL] [Abstract][Full Text] [Related]
2. A possible role of hepcidin in the pathogenesis of anemia among kidney allograft recipients.
Malyszko J; Malyszko JS; Mysliwiec M
Transplant Proc; 2009 Oct; 41(8):3056-9. PubMed ID: 19857675
[TBL] [Abstract][Full Text] [Related]
3. Anemia in heart and kidney allograft recipients: is there a role for hepcidin?
Przybylowski P; Malyszko J; Malyszko JS; Koc-Zorawska E; Sadowski J; Mysliwiec M
Transplant Proc; 2010 Dec; 42(10):4255-8. PubMed ID: 21168677
[TBL] [Abstract][Full Text] [Related]
4. Iron metabolism, hepcidin, and anemia in orthotopic heart transplantation recipients treated with mammalian target of rapamycin.
Przybylowski P; Malyszko JS; Macdougall IC; Malyszko J
Transplant Proc; 2013; 45(1):387-90. PubMed ID: 23375326
[TBL] [Abstract][Full Text] [Related]
5. Hepcidin, an acute-phase protein and a marker of inflammation in kidney transplant recipients with and without coronary artery disease.
Malyszko J; Malyszko JS; Pawlak K; Mysliwiec M
Transplant Proc; 2006 Nov; 38(9):2895-8. PubMed ID: 17112858
[TBL] [Abstract][Full Text] [Related]
6. Hepcidin, iron status, and renal function in chronic renal failure, kidney transplantation, and hemodialysis.
Malyszko J; Malyszko JS; Pawlak K; Mysliwiec M
Am J Hematol; 2006 Nov; 81(11):832-7. PubMed ID: 16929540
[TBL] [Abstract][Full Text] [Related]
7. Anemia is a predictor of outcome in heart transplant recipients.
Przybylowski P; Malyszko J; Malyszko J
Transplant Proc; 2009 Oct; 41(8):3228-31. PubMed ID: 19857717
[TBL] [Abstract][Full Text] [Related]
8. Is hepcidin a link between anemia, inflammation and liver function in hemodialyzed patients?
Małyszko J; Małyszko JS; Hryszko T; Pawlak K; Mysliwiec M
Am J Nephrol; 2005; 25(6):586-90. PubMed ID: 16254410
[TBL] [Abstract][Full Text] [Related]
9. Growth differentiation factor 15 is related to anemia and iron metabolism in heart allograft recipients and patients with chronic heart failure.
Przybyłowski P; Wasilewski G; Bachorzewska-Gajewska H; Golabek K; Dobrzycki S; Małyszko J
Transplant Proc; 2014 Oct; 46(8):2852-5. PubMed ID: 25380934
[TBL] [Abstract][Full Text] [Related]
10. Hemojuvelin and iron metabolism in kidney and heart allograft recipients.
Przybylowski P; Koc-Zorawska E; Glowinska I; Levin-Iaina N; Macdougall IC; Malyszko JS; Mysliwiec M; Malyszko J
Transplant Proc; 2013; 45(1):391-3. PubMed ID: 23375327
[TBL] [Abstract][Full Text] [Related]
11. Type of renal replacement therapy and residual renal function may affect prohepcidin and hepcidin.
Malyszko J; Malyszko JS; Kozminski P; Mysliwiec M
Ren Fail; 2009; 31(10):876-83. PubMed ID: 20030521
[TBL] [Abstract][Full Text] [Related]
12. Serum pro-hepcidin level and iron homeostasis in Japanese dialysis patients with erythropoietin (EPO)-resistant anemia.
Shinzato T; Abe K; Furusu A; Harada T; Shinzato K; Miyazaki M; Kohno S
Med Sci Monit; 2008 Sep; 14(9):CR431-7. PubMed ID: 18758412
[TBL] [Abstract][Full Text] [Related]
13. Serum hepcidin-25 levels and anemia in non-dialysis chronic kidney disease patients: a cross-sectional study.
Uehata T; Tomosugi N; Shoji T; Sakaguchi Y; Suzuki A; Kaneko T; Okada N; Yamamoto R; Nagasawa Y; Kato K; Isaka Y; Rakugi H; Tsubakihara Y
Nephrol Dial Transplant; 2012 Mar; 27(3):1076-83. PubMed ID: 21799206
[TBL] [Abstract][Full Text] [Related]
14. Hepcidin and iron deficiency in pre-kidney transplant patients.
Sancho A; Pastor MC; Troya M; Bonal J; Bayés B; Morales-Indiano C; Lauzurica R; Romero R
Transplant Proc; 2009; 41(6):2079-81. PubMed ID: 19715836
[TBL] [Abstract][Full Text] [Related]
15. Copeptin in relation to New York Heart Association class in heart transplant recipients and kidney transplant recipients.
Malyszko J; Przybylowski P; Koc-Zorawska E; Iaina-Levin N; Sadowski J; Mysliwiec M; Malyszko JS
Transplant Proc; 2010 Dec; 42(10):4259-62. PubMed ID: 21168678
[TBL] [Abstract][Full Text] [Related]
16. Copeptin in heart transplant recipients depends on kidney function and intraventricular septal thickness.
Przybylowski P; Malyszko J; Malyszko JS
Transplant Proc; 2010 Jun; 42(5):1808-11. PubMed ID: 20620528
[TBL] [Abstract][Full Text] [Related]
17. Tumor necrosis factor-related apoptosis-inducing ligand is a marker of kidney function and inflammation in heart and kidney transplant recipients.
Malyszko J; Przybylowski P; Malyszko J; Koc-Zorawska E; Mysliwiec M
Transplant Proc; 2011 Jun; 43(5):1877-80. PubMed ID: 21693293
[TBL] [Abstract][Full Text] [Related]
18. Serum hepcidin: a direct link between anemia of inflammation and coronary artery atherosclerosis in patients with rheumatoid arthritis.
Abdel-Khalek MA; El-Barbary AM; Essa SA; Ghobashi AS
J Rheumatol; 2011 Oct; 38(10):2153-9. PubMed ID: 21885483
[TBL] [Abstract][Full Text] [Related]
19. Serum hepcidin-25 levels in patients with chronic kidney disease are independent of glomerular filtration rate.
Peters HP; Laarakkers CM; Swinkels DW; Wetzels JF
Nephrol Dial Transplant; 2010 Mar; 25(3):848-53. PubMed ID: 19854845
[TBL] [Abstract][Full Text] [Related]
20. Overweight children have higher circulating hepcidin concentrations and lower iron status but have dietary iron intakes and bioavailability comparable with normal weight children.
Aeberli I; Hurrell RF; Zimmermann MB
Int J Obes (Lond); 2009 Oct; 33(10):1111-7. PubMed ID: 19636315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
